猫に有害な薬剤を特定する新テストを開発(New test can flag drugs that could be harmful to cats)

ad

2025-10-27 ワシントン州立大学(WSU)

ワシントン州立大学(WSU)の獣医学研究チームは、猫に有害な薬剤を事前に判定できる新しい遺伝子検査法を開発した。猫の一部では、薬物を排出するための輸送タンパク質ABCB1遺伝子に変異があり、この変異を持つ個体に特定の薬を投与すると、薬剤が脳に蓄積して神経障害や死亡を引き起こす危険がある。研究チームはこの変異を迅速に検出するテストを開発し、試験の結果、変異を持つ猫が複数の鎮痛薬・制吐薬・抗がん剤に対して過敏に反応することを確認した。検査は口腔スワブで実施可能で、臨床現場での応用が容易。これにより、猫への**個別化医療(パーソナライズド・メディスン)**が実現し、薬害事故を大幅に防げると期待される。WSU獣医学部は、全国の動物病院での導入を進めており、ペット医療の安全性と精密化医療の普及に寄与する。成果は『Scientific Reports』誌に掲載。

<関連情報>

ネコP糖タンパク質基質としての臨床的に関連する薬剤の評価
Assessment of clinically relevant drugs as feline P-glycoprotein substrates

Katrina L. Mealey,Neal S. Burke
Frontiers in Veterinary Science  Published:08 October 2025
DOI:https://doi.org/10.3389/fvets.2025.1668282

猫に有害な薬剤を特定する新テストを開発(New test can flag drugs that could be harmful to cats)

Introduction: The drug transporter P-glycoprotein (P-gp) influences drug disposition by playing key roles in limiting brain penetration and enhancing biliary excretion of substrate drugs. Guidance documents from U.S. and European regulatory agencies recommend that manufacturers determine the P-gp substrate status of new medications intended for human patients. The rationale is that P-glycoprotein-mediated drug–drug interactions may cause serious adverse drug events. Unfortunately, the same regulatory guidance does not encompass new feline drugs even though a P-gp knockout mutation (ABCB11930_1931del TC) is present in a subpopulation of cats. Recent reports of a novel macrocyclic lactone, eprinomectin, causing neurological toxicosis in cats homozygous for ABCB11930_1931del TC, imply it is a feline P-gp substrate, but definitive data is lacking, It is intriguing that neurological toxicity has also been reported in a small number of cats treated with amlodipine, capromorelin, and cisapride, however their MDR1 genotypes are unknown.

Methods: A competitive efflux assay and feline P-gp expressing cell line were used to assess the P-gp substrate status of thirteen clinically important drugs used in cats.

Results: Ten drugs, including eprinomectin, were determined to be substrates for feline P-gp while three drugs were not.

Discussion: This information will help improve drug safety for cats with intrinsic (ABCB11930_1931del TC) and acquired P-gp deficiency. Further, this type of assay may be useful for screening feline drug candidates during the drug approval process.

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました